Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    400
  • sponsor
    Atsushi Kawakami
Updated on 10 November 2021
methotrexate
tocilizumab
antirheumatics

Summary

The administration of Janus kinase (JAK) inhibitors as well as biological disease-modifying anti-rheumatic drugs has dramatically improved even the clinical outcomes in rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX). The dysregulation of JAK-signal transducer and activator of transcription (STAT) pathways via overproduction of cytokines, such as interleukin-6 (IL-6) is involved in the pathogenesis of RA. Filgotinib is a selective JAK1 inhibitor to be approved for use in RA. Filgotinib is effective in suppressing disease activity and preventing the progression of joint destruction due to inhibition of the JAK-STAT pathway. IL-6 inhibitors such as tocilizumab also inhibit the JAK-STAT pathways due to inhibition of IL-6 signaling. We will evaluate whether the effectiveness and safety of filgotinib monotherapy is non-inferior to those of tocilizumab monotherapy in RA patients with inadequate response to MTX.

Details
Condition Rheumatoid Arthritis (Pediatric), IL-6 Inhibitor, Musculoskeletal Ultrasound, Rheumatoid Arthritis, Biological Markers, JAK Inhibitor
Treatment filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly
Clinical Study IdentifierNCT05090410
SponsorAtsushi Kawakami
Last Modified on10 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must meet all of the following requirements to be considered for entry into the study
20 years old
with the diagnosis of RA based on the ACR/EULAR 2010 RA Classification Criteria
with at least moderate disease activity defined as a DAS28-ESR 3.2 at the eligibility evaluation
treated with MTX for 8 weeks prior to the providing consent, including 4 weeks or more at the same doses of 8 to 16 mg per week (stable doses of <8 mg per week are allowed only in the presence of intolerance to higher doses)
ability and willingness to provide written informed consent and comply with the requirements of the study protocol

Exclusion Criteria

The exclusion criteria are as follows
concurrent use of a corticosteroid equivalent to >5 mg/day of prednisolone
applicable an item for the contraindication of filgotinib or tocilizumab
a previous use of a JAK inhibitor or IL-6 inhibitor
treatment with a corticosteroid and csDMARD and change of dose within 4 weeks prior to the providing consent
treatment with a biologic DMARD or a biosimilar DMARD (ie, infliximab, biosimilar of infliximab, adalimumab, biosimilar of adalimumab, golimumab, certolizumab pegol or abatacept) within 8 weeks prior to the providing consent
treatment with a TNF inhibitor (ie, etanercept or biosimilar of etanercept) within 4 weeks prior to the providing consent
use of a prohibited drug or therapy, other than the agents noted above, within 4 weeks prior to the providing consent
a complication causing musculoskeletal disorders other than RA (ie, ankylosing spondyloarthritis, reactive arthritis, psoriatic arthritis, crystal-induced arthritis, systemic lupus erythematosus, systemic scleroderma, inflammatory myopathy, or mixed connective tissue disease)
current pregnancy, breastfeeding, or noncompliant with a medically approved contraceptive regimen during and 12 months after the study period
inappropriateness for inclusion in this study as determined by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note